- Home
- NFE vs AUTL Comparison
NFE vs AUTL Comparison
Compare NFE & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFE
- AUTL
- Stock Information
- Founded
- NFE 2014
- AUTL 2014
- Country
- NFE United States
- AUTL United Kingdom
- Employees
- NFE N/A
- AUTL N/A
- Industry
- NFE Oil/Gas Transmission
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NFE Utilities
- AUTL Health Care
- Exchange
- NFE Nasdaq
- AUTL Nasdaq
- Market Cap
- NFE 773.2M
- AUTL 625.4M
- IPO Year
- NFE 2019
- AUTL 2018
- Fundamental
- Price
- NFE $2.44
- AUTL $1.36
- Analyst Decision
- NFE Strong Buy
- AUTL Strong Buy
- Analyst Count
- NFE 6
- AUTL 5
- Target Price
- NFE $8.92
- AUTL $9.12
- AVG Volume (30 Days)
- NFE 24.4M
- AUTL 4.5M
- Earning Date
- NFE 11-06-2025
- AUTL 11-11-2025
- Dividend Yield
- NFE N/A
- AUTL N/A
- EPS Growth
- NFE N/A
- AUTL N/A
- EPS
- NFE N/A
- AUTL N/A
- Revenue
- NFE $2,006,240,000.00
- AUTL $29,934,000.00
- Revenue This Year
- NFE $7.43
- AUTL $641.63
- Revenue Next Year
- NFE $8.38
- AUTL $109.21
- P/E Ratio
- NFE N/A
- AUTL N/A
- Revenue Growth
- NFE N/A
- AUTL 185.17
- 52 Week Low
- NFE $1.26
- AUTL $1.11
- 52 Week High
- NFE $16.66
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- NFE 54.81
- AUTL 33.35
- Support Level
- NFE $1.28
- AUTL $1.26
- Resistance Level
- NFE $2.85
- AUTL $1.46
- Average True Range (ATR)
- NFE 0.30
- AUTL 0.09
- MACD
- NFE 0.08
- AUTL 0.01
- Stochastic Oscillator
- NFE 74.21
- AUTL 30.49
About NFE New Fortress Energy Inc.
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.